CY1107960T1 - Μeθοδος καθαρισμοy της βακτηριακhς κυτταρολυσiνης - Google Patents

Μeθοδος καθαρισμοy της βακτηριακhς κυτταρολυσiνης

Info

Publication number
CY1107960T1
CY1107960T1 CY20081100535T CY081100535T CY1107960T1 CY 1107960 T1 CY1107960 T1 CY 1107960T1 CY 20081100535 T CY20081100535 T CY 20081100535T CY 081100535 T CY081100535 T CY 081100535T CY 1107960 T1 CY1107960 T1 CY 1107960T1
Authority
CY
Cyprus
Prior art keywords
bacterial
bacterial cell
cytarolysin
extract
lysine
Prior art date
Application number
CY20081100535T
Other languages
English (en)
Inventor
Ralph L Biemans
Carine Goraj
Emmanuel Mertens
A Vandercammen
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1107960T1 publication Critical patent/CY1107960T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Η παρούσα δήλωση αναφέρεται σε μια μέθοδο καθαρισμού μιας βακτηριακής κυτταρολυσίνης η οποία περιλαμβάνει τις βαθμίδες α) ανάπτυξης μιας καλλιέργειας κυττάρων που εκφράζουν την βακτηριακή κυτταρολυσίνη, β) μηχανικής θραύσης της καλλιέργειας κυττάρων για να σχηματιστεί ένα εκχύλισμα, γ) προδιήθησης του εκχυλίσματος, δ) σύνδεσης της διαλυτής συσσωματωμένης βακτηριακής κυτταρολυσίνης που περιέχεται στο εκχύλισμα παρουσία απορρυπαντικού σε υλικό χρωματογραφίας υδροφοβικής αλληλεπίδρασης υπό συνθήκες υψηλού άλατος (κατά προτίμηση 0,6-2Μ άλατος), και ε) έκλουσης της βακτηριακής κυτταρολυσίνης παρουσία απορρυπαντικού υπό συνθήκες χαμηλού άλατος (κατά προτίμηση 0-0,2Μ άλατος).
CY20081100535T 2004-09-22 2008-05-26 Μeθοδος καθαρισμοy της βακτηριακhς κυτταρολυσiνης CY1107960T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0421083.7A GB0421083D0 (en) 2004-09-22 2004-09-22 Purification process
EP05797390A EP1791860B1 (en) 2004-09-22 2005-09-20 Purification process for bacterial cytolysin

Publications (1)

Publication Number Publication Date
CY1107960T1 true CY1107960T1 (el) 2013-09-04

Family

ID=33397075

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100535T CY1107960T1 (el) 2004-09-22 2008-05-26 Μeθοδος καθαρισμοy της βακτηριακhς κυτταρολυσiνης

Country Status (15)

Country Link
US (1) US20070231876A1 (el)
EP (1) EP1791860B1 (el)
JP (1) JP4934591B2 (el)
AT (1) ATE393165T1 (el)
CA (1) CA2580113C (el)
CY (1) CY1107960T1 (el)
DE (1) DE602005006294T2 (el)
DK (1) DK1791860T3 (el)
ES (1) ES2304724T3 (el)
GB (1) GB0421083D0 (el)
HR (1) HRP20080242T3 (el)
PL (1) PL1791860T3 (el)
PT (1) PT1791860E (el)
SI (1) SI1791860T1 (el)
WO (1) WO2006032499A1 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004010376T2 (de) 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. Verfahren zur reinigung von bakteriellem cytolysin
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AR058707A1 (es) 2005-12-22 2008-02-20 Glaxosmithkline Biolog Sa Vacuna, procedimiento para fabricarla y su uso
EP2054080A4 (en) * 2006-08-03 2010-11-03 Newcastle Innovation Ltd TREATMENT AND PREVENTION OF ALLERGIC RESPIRATORY DISEASES
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
WO2009094730A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
AU2010290931B2 (en) 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
JP5944480B2 (ja) 2011-03-22 2016-07-05 セルム・インスティテュート・オブ・インディア・ピーブイティー．・リミテッド 多糖を調製するための新規な方法
BR122019017005B1 (pt) * 2011-04-22 2022-03-29 Wyeth Llc Composições que se relacionam a uma toxina de clostridium difficile mutante
AR086405A1 (es) 2011-05-17 2013-12-11 Glaxosmithkline Biolog Sa Vacuna de streptococcus pneumoniae
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3096785B1 (en) 2014-01-21 2020-09-09 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
HRP20230416T1 (hr) 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
CN108367063A (zh) 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
GB201603029D0 (en) * 2016-02-22 2016-04-06 Glaxosmithkline Biolog Sa Vaccine
EP3493840B1 (en) 2016-08-05 2022-08-24 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
BR112019001971A2 (pt) 2016-08-05 2019-05-07 Sanofi Pasteur, Inc. composição conjugada de polissacarídeo-proteína pneumocócica multivalente
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019008564A (es) 2017-01-20 2019-09-19 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas.
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2019152921A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102486891B1 (ko) 2018-02-05 2023-01-10 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
CA3096358A1 (en) 2018-04-18 2019-10-24 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharide and immunogenic conjugate thereof
GB201807303D0 (en) * 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
AU2020323498A1 (en) 2019-07-31 2022-03-03 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
JP2021132644A (ja) 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
TW202304503A (zh) 2021-05-28 2023-02-01 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006951A1 (en) * 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
DE4133707A1 (de) * 1991-10-11 1993-04-15 Behringwerke Ag Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung
US5652125A (en) * 1996-06-10 1997-07-29 Pharmacia S.P.A. Process for preparing daunorubicin
JP2001510031A (ja) * 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物
DE602004010376T2 (de) * 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. Verfahren zur reinigung von bakteriellem cytolysin
JP4578067B2 (ja) * 2003-06-06 2010-11-10 宏 清水 局所医薬組成物

Also Published As

Publication number Publication date
PL1791860T3 (pl) 2008-09-30
JP4934591B2 (ja) 2012-05-16
PT1791860E (pt) 2008-05-20
DE602005006294T2 (de) 2008-08-14
DE602005006294D1 (de) 2008-06-05
WO2006032499A1 (en) 2006-03-30
US20070231876A1 (en) 2007-10-04
ATE393165T1 (de) 2008-05-15
ES2304724T3 (es) 2008-10-16
EP1791860B1 (en) 2008-04-23
CA2580113C (en) 2018-01-16
CA2580113A1 (en) 2006-03-30
DK1791860T3 (da) 2008-07-14
GB0421083D0 (en) 2004-10-27
HRP20080242T3 (en) 2008-09-30
SI1791860T1 (sl) 2008-08-31
JP2008513408A (ja) 2008-05-01
EP1791860A1 (en) 2007-06-06

Similar Documents

Publication Publication Date Title
CY1107960T1 (el) Μeθοδος καθαρισμοy της βακτηριακhς κυτταρολυσiνης
CR8998A (es) PRODUCCION DE TNFR-Ig Y FUSION DE PROTEINA
Tay et al. A synthetic circuit for mercury bioremediation using self-assembling functional amyloids
CR8997A (es) Produccion de polipeptidos
Dayton et al. A calcium-activated protease possibly involved in myofibrillar protein turnover. Isolation of a low-calcium-requiring form of the protease
Schmidt et al. Diagenetic transformation of dissolved organic nitrogen compounds under contrasting sedimentary redox conditions in the Black Sea
BR9910332A (pt) Polipeptìdio, composição, método para purificação de polipeptìdio a partir de uma composição e método para purificação de um anticorpo a partir de uma composição
CR8996A (es) PRODUCCION DE a-BETA
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
HRP20030088B1 (hr) Anti-dvostruka integrinska protutijela, pripravci, postupci i primjena
JOP20080381B1 (ar) بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
DK1395648T3 (da) Fremgangsmåder til binding af AcmA-type proteinankerfusioner til cellevægsmateriale af mikroorganismer
WO2007067983A3 (en) Sulfotyrosine specific antibodies and uses therefor
Oren et al. Red/far-red light signals regulate the activity of the carbon-concentrating mechanism in cyanobacteria
Johnson et al. The carboxyl terminus of the ε subunit of the chloroplast ATP synthase is exposed during illumination
DK1576157T3 (da) Fluorescerende proteiner fra Copepode-arter og fremgangsmåder til anvendelse af samme
Saunders et al. Proteomic and Computational Analysis of Secreted Proteins with Type I Signal Peptides from the Antarctic Archaeon Methanococcoides b urtonii
AU2174002A (en) Method for analyzing proteins
Bolliger et al. Re-examining the glomalin-purity of glomalin-related soil protein fractions through immunochemical, lectin-affinity and soil labelling experiments
Helmerhorst Whole saliva proteolysis: wealth of information for diagnostic exploitation
DE602004015629D1 (de) Ansfertest
Hayley et al. Biochemical analysis of a Ca2+‐dependent membrane–membrane interaction mediated by the sea urchin yolk granule protein, toposome
WO2006127682A3 (en) Novel methods
EP2407787A3 (en) Method for detection of L523S expression in biological samples